Behind the Scenes

Essais extraits du podcast de Rob Mac Sweeney

• 2021REMAP-CAPICU & Critical CareIn895 critically ill adults with Covid-19 on organ support,tocilizumab or sarilumabincreasedorgan support-free days and survivalversusstandard care
• 2025REMAP-CAPICU & Critical CareIn 2274 critically ill patients with COVID-19, anakinra did not increase organ support-free days or survival compared with no immune modulator.
• 2021REMAP-CAPICU & Critical CareIn 694 critically ill adults with COVID-19, lopinavir-ritonavir or hydroxychloroquine reduced organ support-free days versus no antiviral therapy.
• 2021ATTACC/ACTIV-4a/REMAP-CAPAnticoagulation & AntithromboticsIn 2219 non-critically ill patients hospitalised with Covid-19, therapeutic-dose heparin increased organ support-free days versus usual-care thromboprophylaxis.
• 2021REMAP-CAPICU & Critical CareIn 2011 critically ill adults with COVID-19, convalescent plasma did not increase organ support-free days compared with no convalescent plasma.
• 2022REMAP-CAPICU & Critical CareIn 1557 critically ill adults with COVID-19, antiplatelet therapy did not increase organ support-free days within 21 days compared with no antiplatelet agent.
• 2020REMAP-CAP Corticosteroid DomainICU & Critical CareIn 403 critically ill adults with severe COVID-19, hydrocortisone did not significantly improve organ support–free days compared with no hydrocortisone.